HUMAN CYTOCHROME P450 INHIBITION AND METABOLIC-INTERMEDIATE COMPLEX FORMATION BY GOLDENSEAL EXTRACT AND ITS METHYLENEDIOXYPHENYL COMPONENTS

Publisher Website
Google Scholar
Abstract
The concurrent use of herbal medicinals with prescription and over-the-counter drugs carries a risk for unanticipated adverse drug-botanical pharmacokinetic interactions, particularly as a result of cytochrome P450 (P450) inhibition. Extracts of goldenseal (Hydrastis canadensis) containing approximately equal concentrations (∼17 mM) of two methylenedioxyphenyl alkaloids, berberine and hydrastine, inhibited with increasing potency (CYP2C9) diclofenac 4′-hydroxylation, (CYP2D6) bufuralol 1′-hydroxylation, and (CYP3A4) testosterone 6β-hydroxylation activities in human hepatic microsomes. The inhibition of testosterone 6β-hydroxylation activity was noncompetitive with an apparent Ki of 0.11% extract. Of the methylenedioxyphenyl alkaloids, berberine (IC50 = 45 μM) was the more inhibitory toward bufuralol 1′-hydroxylation and hydrastine (IC50 ∼350 μM for both isomers), toward diclofenac 4′-hydroxylation. For testosterone 6β-hydroxylation, berberine was the least inhibitory component (IC50 ∼400 μM). Hydrastine inhibited testosterone 6β-hydroxylation with IC50 values for the (+)- and (-)-isomers of 25 and 30 μM, respectively. For (-)-hydrastine, an apparent Ki value of 18 μM without preincubation and an NADPH-dependent mechanism-based inhibition with a kinactivation of 0.23 min-1 and a KI of ∼110 μM were determined. Cytochrome P450 metabolic-intermediate (MI) complex formation could be demonstrated for both hydrastine isomers. With expressed P450 isoforms, hydrastine formed a P450 MI complex with CYP2C9, CYP2D6, and CYP3A4. Coexpression of cytochrome b5 with the P450 isoforms enhanced the rate but not the extent of P450 MI complex formation.

This publication has 17 references indexed in Scilit: